This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lopez-Serra, L. Articles by Esteller, M. Search for Related Content PubMed PubMed Citation Articles by Lopez-Serra, L. Articles by Esteller, M.

A Profile of Methyl-CpG Binding Domain Protein Occupancy of Hypermethylated Promoter CpG Islands of Tumor Suppressor Genes in Human Cancer

¹ Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain and ² Department of Histology, University of Granada, and Fundacion Hospital Clinico, Granada, Spain

Requests for reprints: Manel Esteller, Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, 28029 Madrid, Spain. Phone: 34-91-224-69-40; Fax: 34-91-224-6923; E-mail: mesteller{at}cnio.es.

Methyl-CpG binding domain (MBD) proteins have been shown to couple DNA methylation to transcriptional repression. This biological property suggests a role for MBD proteins in the silencing of tumor suppressor genes that are hypermethylated at their promoter CpG islands in cancer cells. Despite the demonstration of the presence of MBDs in the methylated promoter of several genes, we still ignore how general and specific is this association. Here, we investigate the profile of MBD occupancy in a large panel of tumor suppressor gene promoters and cancer cell lines. Our study shows that most hypermethylated promoters are occupied by MBD proteins, whereas unmethylated promoters are generally devoid of MBDs, with the exception of MBD1. Treatment of cancer cells with the demethylating agent 5-aza-2'-deoxycytidine results in CpG island hypomethylation, MBD release, and gene reexpression, reinforcing the notion that association of MBDs with methylated promoters is methylation-dependent. Whereas several promoters are highly specific in recruiting a particular set of MBDs, other promoters seem to be less exclusive. Our results indicate that MBDs have a great affinity in vivo for binding hypermethylated promoter CpG islands of tumor suppressor genes, with a specific profile of MBD occupancy that it is gene and tumor type specific. (Cancer Res 2006; 66(17): 8342-6)

This article has been cited by other articles:

				A. Chatagnon, S. Bougel, L. Perriaud, J. Lachuer, J. Benhattar, and R. Dante Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells Carcinogenesis, January 1, 2009; 30(1): 28 - 34. [Abstract] [Full Text] [PDF]

				W. Ji, L. Yang, L. Yu, J. Yuan, D. Hu, W. Zhang, J. Yang, Y. Pang, W. Li, J. Lu, et al. Epigenetic silencing of O6-methylguanine DNA methyltransferase gene in NiS-transformed cells Carcinogenesis, June 1, 2008; 29(6): 1267 - 1275. [Abstract] [Full Text] [PDF]

				H. Zou, J. Harrington, R. L. Rego, and D. A. Ahlquist A Novel Method to Capture Methylated Human DNA from Stool: Implications for Colorectal Cancer Screening Clin. Chem., September 1, 2007; 53(9): 1646 - 1651. [Abstract] [Full Text] [PDF]

				M. Esteller Epigenetic gene silencing in cancer: the DNA hypermethylome Hum. Mol. Genet., April 15, 2007; 16(R1): R50 - R59. [Abstract] [Full Text] [PDF]